FDA/NIH INFORMED CONSENT REGS TO BE RECONCILED AT CONSENSUS WORKSHOP; EMERGENCY RESEARCH GUIDE NEEDS REVISION IN LIGHT OF TREATMENT ADVANCES -- FDAer
FDA and the National Institutes of Health will try to reconcile their informed consent regulations at a workshop expected to be held sometime this fall for patients, physicians, ethicists and members of Institutional Review Boards, FDA Deputy Commissioner Mary Pendergast told a May 23 hearing of Rep. Wyden's (D-Ore.) House Small Business/Regulation Subcommittee.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth